Zydus Lifesciences Limited, listed on NSE under the symbol ZYDUSLIFE and on BSE under scrip code 532321, has increased its buyback price to Rs 1,260 per equity share from Rs 1,150. The Buyback Committee approved the revision at its meeting on May 27, 2026. The revised price is Rs 110 per share higher than the original offer announced on May 20, 2026.
The aggregate buyback outlay remains capped at approximately Rs 1,100 crore. The maximum number of equity shares to be bought back has been reduced to 87,30,158 shares from the earlier 95,65,217 shares. This represents up to 0.87% of the total paid-up equity share capital.
Each equity share carries a face value of Re 1. The buyback will be executed through the tender offer route on a proportionate basis. Zydus Lifesciences had previously communicated the buyback proposal through exchange letters dated May 13, May 19, and May 21, 2026.
The public announcement was published on May 21, 2026. The board of directors had originally approved the buyback of up to 95,65,217 shares at Rs 1,150 each, and the Buyback Committee was authorized to finalize the terms.
The addendum to the public announcement will be published in Financial Express (English, all editions), Jansatta (Hindi, all editions), and Financial Express (Gujarati, Ahmedabad edition). The documents will be available on the Zydus Lifesciences website, the ICICI Securities website as manager to the buyback, and the SEBI website during the buyback period.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.